This is the authors' abstract. We don't add key points for this paper.
The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism, but did not induce vasodilation at the maximum feasible dose. Moreover, preadministration of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD2. This profile made 5a a suitable candidate for further study for the treatment of dyslipidemia.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Semple et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: